| Literature DB >> 34373668 |
Jessica Bourque1, Daniel Hawiger1.
Abstract
Despite substantial progress in developing new immunotherapies against multiple sclerosis (MS), currently available immunotherapies are only partially effective for this debilitating neurological disease, thus necessitating new therapeutic approaches. Here, we review the immunotherapies already approved for MS as well as relevant clinical trials. Further, we present some experimental approaches that are currently being developed and are focused on modulating the functions of dendritic cells and regulatory T cells. Copyright 2021 by the Missouri State Medical Association.Entities:
Year: 2021 PMID: 34373668 PMCID: PMC8343631
Source DB: PubMed Journal: Mo Med ISSN: 0026-6620